Holen Sie sich die Stockscreener-App
79.92
1.46%
1.15
Schlusskurs vom Vortag:
$78.77
Offen:
$78.54
24-Stunden-Volumen:
1.85M
Relative Volume:
1.08
Marktkapitalisierung:
$14.47B
Einnahmen:
$342.96M
Nettoeinkommen (Verlust:
$-864.29M
KGV:
-14.40
EPS:
-5.55
Netto-Cashflow:
$-636.03M
1W Leistung:
+4.40%
1M Leistung:
-1.41%
6M Leistung:
+7.69%
1J Leistung:
+203.42%
1-Tages-Spanne:
$78.00
$81.19
1-Wochen-Bereich:
$75.23
$81.19
52-Wochen-Spanne:
$21.92
$84.91
Insmed Inc Stock (INSM) Company Profile
Firmenname
Insmed Inc
Sektor
Branche
Telefon
908-977-9900
Adresse
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Vergleichen Sie INSM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
79.92 | 14.47B | 342.96M | -864.29M | -636.03M | -5.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
503.20 | 129.22B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
658.48 | 71.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
615.02 | 37.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
283.34 | 36.68B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
251.98 | 27.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-04-23 | Eingeleitet | Truist | Buy |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-07-26 | Eingeleitet | Guggenheim | Buy |
| 2022-12-09 | Eingeleitet | Mizuho | Buy |
| 2022-12-07 | Eingeleitet | Barclays | Overweight |
| 2022-11-18 | Eingeleitet | BofA Securities | Buy |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2021-12-06 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-19 | Fortgesetzt | Monness Crespi & Hardt | Buy |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-10-12 | Fortgesetzt | Stifel | Buy |
| 2019-09-03 | Eingeleitet | Goldman | Buy |
| 2019-04-09 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-15 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | Hochstufung | Goldman | Neutral → Buy |
| 2019-01-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2018-08-06 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | Eingeleitet | Goldman | Neutral |
| 2018-04-23 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-01-18 | Eingeleitet | Credit Suisse | Neutral |
| 2017-09-05 | Bestätigt | Evercore ISI | Outperform |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-07-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2016-03-15 | Eingeleitet | Stifel | Buy |
| 2015-11-09 | Herabstufung | UBS | Buy → Neutral |
| 2015-10-06 | Bestätigt | H.C. Wainwright | Buy |
| 2015-06-09 | Eingeleitet | Citigroup | Neutral |
| 2014-03-26 | Bestätigt | HC Wainwright | Buy |
Alle ansehen
Insmed Inc Aktie (INSM) Neueste Nachrichten
Insmed’s SWOT analysis: rare disease biotech stock poised for growth By Investing.com - Investing.com Canada
Insmed’s SWOT analysis: rare disease biotech stock poised for growth - Investing.com
Insmed reports preclinical data on INS-1201 for DMD - BioWorld Online
Insmed CEO William Lewis sells $1.97 million in stock By Investing.com - Investing.com Australia
Insmed’s stock should triple after positive drug trial data, analyst says - MSN
H.C. Wainwright maintains Buy on Insmed stock, $90 target By Investing.com - Investing.com Canada
Insmed CEO William Lewis sells $1.97 million in stock - Investing.com India
Expert Outlook: Insmed Through The Eyes Of 13 Analysts - Benzinga
RBC maintains Outperform on Insmed stock, price target at $100 By Investing.com - Investing.com Canada
Insmed Incorporated (INSM): Among the Best Biotech Stocks to Buy According to Billionaires - Yahoo Finance
15 Best Biotech Stocks to Buy According to Billionaires - Insider Monkey
Truist maintains Buy on Insmed stock, sees PAH data as positive - Investing.com Australia
US Bancorp DE Boosts Holdings in Insmed Incorporated (NASDAQ:INSM) - Defense World
Truist maintains Buy on Insmed stock, sees PAH data as positive By Investing.com - Investing.com South Africa
Insmed at Leerink Global Healthcare Conference: Optimism for Brenzo’s Launch By Investing.com - Investing.com South Africa
Insider Sell: Roger Adsett Sells 42,975 Shares of Insmed Inc (IN - GuruFocus.com
Insmed at Leerink Global Healthcare Conference: Optimism for Brenzo’s Launch - Investing.com
Insmed Incorporated (NASDAQ:INSM) Shares Acquired by Smartleaf Asset Management LLC - Defense World
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Citizentribune
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) -March 10, 2025 at 08:01 am EDT - Marketscreener.com
Insmed Expands Team with Stock Options Grant to 18 New Hires - StockTitan
UBS Group Raises Insmed (NASDAQ:INSM) Price Target to $110.00 - Defense World
Insmed’s Strategic Growth and Promising Pipeline Drive Buy Rating - TipRanks
UBS raises Insmed stock price target to $110 By Investing.com - Investing.com UK
Insmed CEO Lewis sells $1.99 million in stock By Investing.com - Investing.com Australia
Insmed CEO Lewis sells $1.99 million in stock - Investing.com India
Amalgamated Bank Boosts Stake in Insmed Incorporated (NASDAQ:INSM) - Defense World
Sanctuary Advisors LLC Acquires 464 Shares of Insmed Incorporated (NASDAQ:INSM) - Defense World
Insmed, Agios rise; DraftKings, Atlantica fall, Tuesday, 5/28/2024 - Star Tribune
RBC Capital starts Insmed at Outperform on brensocatib launch momentum - MSN
Guggenheim Reaffirms Buy Rating for Insmed (NASDAQ:INSM) - MarketBeat
Investor Network: Insmed Incorporated to Host Earnings Call - ACCESS Newswire
Major Public Health Interest? Scholar, Insmed & Soleno Ask EMA To Fast-Track Their Products - Pink Sheet
Truist Financial Corp Boosts Stake in Insmed Incorporated (NASDAQ:INSM) - Defense World
Insmed (NASDAQ:INSM) Now Covered by Royal Bank of Canada - MarketBeat
Insmed's Q4 Loss Wider Than Expected, Sales In Line With Estimates - MSN
RBC Capital Initiates Coverage of Insmed (LSE:0JAV) with Outperform Recommendation - Nasdaq
Lung Disease-Focused Insmed 'Is An Attractive Midcap Biotech,' Analyst Says - Benzinga India
RBC Capital sets $100 price target on Insmed stock with Outperform rating - Investing.com Canada
RBC Capital Initiates Coverage of Insmed (INSM) with Outperform Recommendation - MSN
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Insmed to Benefit From Strong Launch of Brensocatib for Lung Disease, RBC Says -February 25, 2025 at 12:09 pm EST - Marketscreener.com
FDA sets PDUFA date for Insmed's bronchiectasis drug By Investing.com - Investing.com Australia
FDA sets PDUFA date for Insmed’s bronchiectasis drug By Investing.com - Investing.com Nigeria
Insmed’s Brensocatib Receives FDA Priority Review - TipRanks
International Markets and Insmed (INSM): A Deep Dive for Investors - Yahoo Finance
FDA sets PDUFA date for Insmed's bronchiectasis drug - Investing.com India
FDA sets PDUFA date for Insmed’s bronchiectasis drug - Investing.com
Could This Novel Drug Transform Bronchiectasis Treatment? FDA Signals Confidence in Brensocatib - StockTitan
Insider Sell: Sara Bonstein Sells 18,322 Shares of Insmed Inc (I - GuruFocus.com
Finanzdaten der Insmed Inc-Aktie (INSM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Insmed Inc-Aktie (INSM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lewis William | Chair and CEO |
Mar 17 '25 |
Option Exercise |
10.85 |
6,830 |
74,106 |
240,754 |
| Lewis William | Chair and CEO |
Mar 17 '25 |
Sale |
77.03 |
18,750 |
1,444,241 |
334,186 |
| Lewis William | Chair and CEO |
Mar 17 '25 |
Sale |
77.04 |
6,830 |
526,179 |
233,924 |
1.59%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):